Application of rhizoma bletillae polysaccharide in preparation of medicine for treating postoperative wound surface under digestive endoscopy

By spraying postoperative wounds with high-purity white and polysaccharides under digestive endoscopy, the problems of bleeding and perforation after ESD were solved, and the wound healing and bleeding rate was reduced, showing that white and polysaccharides in digestive endoscopy treatment innovative applications and practical effects.

CN118987022APending Publication Date: 2024-11-22THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV OF TCM
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411257681.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Complications such as wound bleeding and perforation after ESD surgery are difficult to effectively prevent. The existing technologies such as proton pump inhibitors, titanium clip closure and electrocoagulation methods are insufficient, and emerging wound coverings are costly and cumbersome, and have not been widely promoted in clinical practice. .

Method used

High-purity white and polysaccharides are sprayed on the postoperative wound under digestive endoscopy. Through its procoagulant, anti-inflammatory and mucosal protective effects, it promotes wound healing and reduces scars, which is low in cost and easy to operate.

Benefits of technology

Effectively reduce the rate of postoperative wound bleeding, promote wound healing, reduce the risk of postoperative complications, is simple to operate, has high safety, and has clinical promotion value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005034576470000041
    Figure BDA0005034576470000041
Patent Text Reader

Abstract

The invention relates to application of rhizoma bletillae polysaccharide in preparation of a medicine for treating postoperative wounds under a digestive endoscopy, and can effectively solve the problems that large wounds are difficult to treat after EMR and ESD operations and large esophageal wounds are easy to narrow after healing at present, and the technical scheme for solving the problems is that the purity of the rhizoma bletillae polysaccharide is 99%, and the dosage of the rhizoma bletillae polysaccharide is 1g / 2-5cm < 2 >. The rhizoma bletillae polysaccharide disclosed by the invention is relatively low in cost, and the rhizoma bletillae polysaccharide can be used for preparing a medicine for treating the postoperative wounds under the digestive endoscopy. The bletilla striata polysaccharide is simple in production process, easy and convenient to use under an endoscope, capable of being sprayed on the surface of gastrointestinal ulcer, easy to operate and good in adhesion, plays a positive role in wound repair while stopping bleeding, can relieve scars, is good in using effect and high in practicability, is an innovation of postoperative wound drugs for treatment under the digestive endoscope, and develops new application of the bletilla striata polysaccharide.
Need to check novelty before this filing date? Find Prior Art

Description

1. Technical Field

[0001] The invention relates to the field of digestive endoscopy, in particular to the application of Bletilla striata polysaccharide in the preparation of a medicine for treating postoperative wounds under digestive endoscopy. 2. Background Technology

[0002] The main purpose of clinical gastroenteroscopy is to diagnose and endoscopically treat gastrointestinal lesions. Among them, common endoscopic resection methods include biopsy forceps, high-frequency electric snare resection, argon plasma scalpel therapy (APC), endoscopic mucosal resection (EMR), and endoscopic submucosal dissection (ESD). Among them, the treatment of large wounds after submucosal injection and resection is the key point in EMR and ESD, and is also a hot topic in current research. However, the wound after ESD is large and deep, which is easy to cause complications such as postoperative wound bleeding, perforation, and wound stenosis. Among them, postoperative wound bleeding is the most common and important complication. It has been reported that the median bleeding rate of gastric wound after ESD is about 5% (range 0% to 15.6%), and the risk of postoperative wound bleeding in patients with antithrombotic therapy can reach 21% to 38%. Traditional methods of titanium clips or electrocoagulation of exposed blood vessels in the wound are difficult to prevent postoperative large wound bleeding. Excessive bleeding may be life-threatening and requires intervention such as blood transfusion, interventional hemostasis, or surgery.

[0003] Currently, the commonly used methods for preventing post-ESD bleeding are: (1) Oral administration of proton pump inhibitors (PPIs) after surgery, which inhibits gastric acid secretion by inhibiting H+-K+-ATPase on gastric parietal cells, increases gastric pH and prevents blood clot dissolution, while promoting the healing of ulcers after ESD. However, proton pump inhibitors can cause abdominal pain, bloating and other discomforts in some patients, and endoscopic mucosal resection can also cause abdominal pain and bloating in patients. Therefore, oral administration of these drugs after surgery will aggravate patients' abdominal pain, bloating and other digestive discomforts. (2) Sealing the mucosal defect on the ulcer surface with titanium clips. However, for larger ulcers, it is difficult to seal with titanium clips alone. Often, multiple titanium clips combined with nylon rings are required to close the wound surface. In addition, the field of view under endoscopic operation is limited, and some titanium clips have technical difficulties in closing, which increases the operation time and the difficulty of operation. At the same time, the duration of titanium clip closure is still unclear. (3) Electrocoagulation of exposed blood vessels on the ulcer surface. Its main disadvantage is microvascular damage on the wound surface and reduced blood supply under the ulcer bed, resulting in poor ulcer healing. It may even lead to transmural electrocoagulation injury on the ulcer surface, which is also one of the important causes of postoperative wound bleeding and perforation. (4) Stop antithrombotic therapy before surgery. Takizawa et al. believed that stopping antithrombotic therapy before surgery can reduce the risk of postoperative wound bleeding (OR 1.27-4.80), but related studies have shown that stopping aspirin can increase the risk of embolism such as cardiovascular events and cerebral infarction by about 3 times. The guidelines of the British Society of Gastroenterology and the European Society of Gastrointestinal Endoscopy also emphasize that interruption of antithrombotic therapy can increase the risk of thromboembolism.

[0004] Therefore, it is necessary to adopt a new method to prevent postoperative wound bleeding after ESD. At present, many new research and development of wound coverings are being carried out to prevent complications such as postoperative wound bleeding and perforation. Currently, wound coverings mainly include the following four types: (1) PGA; (2) fibrin glue (FG); (3) medical adhesives; (4) hemostatic powder. These wound coverings have the problems of high cost and cumbersome procedures, and have not been widely promoted in clinical practice.

[0005] Bletilla striata polysaccharide is the main active ingredient of Bletilla striata. It is a neutral heteropolysaccharide after Bletilla striata powder is not purified by water extraction. It is also called Bletilla striata glue and Bletilla striata glucomannan. It is composed of a-mannose, 3-mannose and B-glucose bonded by 1→4 glycosidic bonds, and its molecular weight is between tens of thousands and hundreds of thousands of Da. Studies have shown that Bletilla striata polysaccharide has a variety of biological activities, including procoagulant, antibacterial, anti-inflammatory, antioxidant, anti-tumor, mucosal protection, and immunomodulation. The chemical structure of Bletilla striata polysaccharide has the characteristics of easy modification, low immunogenicity, biocompatibility, and biodegradability. Bletilla striata / Bletilla striata polysaccharide plays a positive role in all stages of wound repair, including coagulation stage, inflammation stage, proliferation stage, and remodeling stage. It is used for spraying wounds after ESD lesion peeling, mainly using it as a neutral heteropolysaccharide, which can form a gel-like substance with good adhesion when it comes into contact with water. And its possible promotion role in the wound repair period.

[0006] Recently, related studies have prepared Bletilla striata polysaccharide into capsules for oral administration for wound repair after ESD surgery: it was found that the efficacy of combined use of esomeprazole enteric-coated tablets in the treatment of artificial ulcers after gastric ESD surgery was better than that of esomeprazole enteric-coated tablets alone. It can further reduce the ulcer area, promote ulcer healing and regeneration of surrounding mucosa, increase the ulcer inhibition rate, and reduce the incidence of protrusions at the base of ulcers. However, there are currently no reports on its application in the treatment of postoperative wounds under gastrointestinal endoscopy. III. Summary of the invention

[0007] In view of the above situation, in order to solve the defects of the prior art, the purpose of the present invention is to provide a Bletilla striata polysaccharide for use in the preparation of drugs for the treatment of postoperative wounds under digestive endoscopy, which can effectively solve the current problems of large wounds being difficult to treat after EMR and ESD surgery, and the problem that large esophageal wounds are prone to stenosis after healing.

[0008] The technical solution solved by the present invention is the application of Bletilla striata polysaccharide in the preparation of medicine for treating postoperative wounds under digestive endoscopy.

[0009] The purity of the Bletilla polysaccharide is 99%, and the dosage is 1g / 2-5cm 2 .

[0010] The preparation method of the polysaccharide of Bletilla striata is as follows: using 10 times the amount of distilled water to ultrasonically extract twice at 55°C, each time for 60 minutes, filtering, combining the filtrate, adjusting the pH of the filtrate to 6.5 with a 20% hydrochloric acid solution or a 20% sodium hydroxide solution, adding 3‰ (w / v) of medium-temperature a-amylase, hydrolyzing in a 60°C water bath for 3 hours, and then adjusting the pH to 7.5, and adjusting the substrate concentration to 4 mg·100 mL -1 , add 3% (w / v) plant protease, stir and enzymolyze in a 45°C water bath for 3 hours, coarsely filter, ultrafilter with a 10,000 molecular weight ultrafiltration membrane, continue to reduce pressure and concentrate the filtrate to a thick paste, and then dry and crush in a vacuum drying oven to obtain the product.

[0011] The Bletilla striata polysaccharide of the present invention has low cost, simple production process, and is easy to use under endoscopy. It can be sprayed on the surface of gastrointestinal ulcers, is easy to operate, has good adhesion, and while stopping bleeding, also plays a positive role in wound repair and can reduce scars. It has good use effect and strong practicality. It is an innovation in drugs for postoperative wounds in digestive endoscopy treatment, and a new use of Bletilla striata polysaccharide has been developed. 4. Specific implementation methods

[0012] The specific implementation modes of the present invention are further described in detail below in conjunction with the embodiments.

[0013] The present invention is the first to discover the use of Bletilla striata polysaccharide in the preparation of a drug for treating postoperative wounds under digestive endoscopy. In the face of the patient's original ulcer wound or the artificial ulcer wound caused by EMR or ESD surgery, a small amount of high-purity sterile Bletilla striata polysaccharide powder is evenly sprayed on the wound under endoscopy. Bletilla striata polysaccharide can also be purchased commercially, is easy to use under endoscopy, sprayed on the surface of gastrointestinal ulcers, is simple to operate, has good adhesion, and while stopping bleeding, also plays a positive role in wound repair and can reduce scars. The relevant test data are as follows:

[0014] 1. The effect of Bletilla striata polysaccharide sprayed directly on the postoperative wound under digestive endoscopy

[0015] 1. Objects and Methods

[0016] 1.1 Research subjects

[0017] There were 12 experimental pigs, half of which were male and half were female, with an average weight of 25-30 kg.

[0018] 1.2 Experimental methods

[0019] 1.2.1 Experimental Grouping

[0020] Twelve experimental pigs, half male and half female, were randomly divided into two groups (n=6): an experimental group and a control group.

[0021] Postoperative treatment of the experimental group: after complete resection, electrocoagulation hemostasis or titanium clip closure of the wound was performed according to the wound surface condition;

[0022] Postoperative treatment of the control group: After complete resection, 2 g of Bletilla striata polysaccharide powder was evenly sprayed on the postoperative surface through the working channel of the endoscope under continuous airflow after conventional electrocoagulation hemostasis. Bletilla striata polysaccharide can also be purchased commercially.

[0023] 1.2.2 Preoperative preparation

[0024] (1) The experimental pigs were fasted for 48 hours before surgery;

[0025] (2) The pig legs were skinned before the experiment;

[0026] (3) The pig was placed in the left lateral decubitus position and a single intravenous injection of sodium pentobarbital (20 mg / kg) was given;

[0027] (4) Connect to an anesthesia ventilator, continuously inject sodium pentobarbital (5 mg / kg / h) intravenously, perform routine endotracheal intubation, and connect to an ECG monitor;

[0028] (5) After installing the endoscope, connect the suction device, electroresection and electrocoagulation equipment, connect the electrode plate and stick it to the prepared skin;

[0029] (6) Connect the special syringe containing the injection material to the 23G needle;

[0030] (7) Prepare instruments related to endoscopic surgery.

[0031] 1.2.3 Experimental content

[0032] (1) Pig stomach ESD experiment: Each experimental pig was subjected to ESD. A 2 cm*2 cm area of ​​mucosa was selected from the same part of the esophagus and stomach for ESD resection, i.e., 12 wounds in each group. Reexamination was performed 1 and 2 weeks after surgery.

[0033] (2) Monitoring postoperative bleeding

[0034] (3) Monitoring postoperative healing

[0035] 2. Experimental Results

[0036] (1) One week after surgery, there was a significant difference in wound healing rate between the two groups (P<0.05);

[0037] (2) The bleeding rates in both groups were low;

[0038] (3) No serious postoperative complications such as perforation and infection occurred in either group.

[0039] Table 1 Wound healing rate

[0040]

[0041] Conclusion

[0042] The present invention uses high-purity sterile Bletilla striata polysaccharide powder to evenly spray on the wound surface of the patient's original ulcer wound surface or the artificial ulcer wound surface caused by EMR or ESD surgery under digestive endoscopy, which can effectively promote wound healing with a low bleeding rate and no other obvious complications after surgery. The safety of using Bletilla striata polysaccharide on digestive tract wound surfaces is verified, and the operation is simple and the adhesion is good. While stopping bleeding, it also plays a positive role in wound repair and can reduce scars. The invention has practical clinical significance and promotion and application value.

[0043] It should be pointed out that the above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Any technician familiar with the profession can make changes or modify the technical contents disclosed above into equivalent embodiments with equivalent changes without departing from the scope of the technical solution of the present invention, which all fall within the protection scope of the present invention.

Claims

1. Application of Bletilla striata polysaccharide in the preparation of drugs for the treatment of postoperative wounds during digestive endoscopy.

2. The use of the Bletilla striata polysaccharide according to claim 1 in the preparation of a drug for treating postoperative wounds under digestive endoscopy, characterized in that: The purity of the Bletilla polysaccharide is 99%, and the dosage is 1g / 2-5cm 2 .

3. The use of Bletilla striata polysaccharide according to claim 1 in the preparation of a drug for treating postoperative wounds under digestive endoscopy, characterized in that: The preparation method of Bletilla striata polysaccharide is as follows: use 10 times the amount of distilled water to perform ultrasonic extraction twice at 55°C, each time for 60 minutes, filter, combine the filtrate, adjust the pH of the filtrate to 6.5 with 20% hydrochloric acid solution or 20% sodium hydroxide solution, add 3‰ mesophilic α-amylase, hydrolyze in a 60°C water bath for 3 hours, then adjust the pH to 7.5, and adjust the substrate concentration to 4 mg•100 mL -1 , add 3% plant protease, stir and enzymolyze in a 45°C water bath for 3 hours, coarsely filter, ultrafilter with a 10,000 molecular weight ultrafiltration membrane, continue to reduce pressure and concentrate the filtrate to a thick paste, and then dry and crush in a vacuum drying oven to obtain the product.